Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
Camille Moeckel, Katrina Bakhl, Ilias Georgakopoulos-Soares, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6710-6710
Open Access | Times Cited: 24

Showing 24 citing articles:

Artificial Intelligence and Machine Learning in Predicting the Response to Immunotherapy in Non-small Cell Lung Carcinoma: A Systematic Review
Tanya Sinha, Aiman Khan, Manahil Awan, et al.
Cureus (2024)
Open Access | Times Cited: 6
Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
Paraskevi Vryza, Timo Fischer, Elena Mistakidi, et al.
Translational Oncology (2023) Vol. 38, pp. 101788-101788
Open Access | Times Cited: 15
Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors
Luciana Alexandra Pavelescu, Robert Mihai Enache, Oana Alexandra Roşu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9659-9659
Open Access | Times Cited: 5
Multi-omics analysis reveals lysosome-associated molecular subtype characterization and prognostic modeling system in lung adenocarcinoma
Zhanmei Wang, Yan Wang, Jinxiang Wang
Journal of Cancer (2025) Vol. 16, Iss. 6, pp. 1794-1813
Open Access
Comprehensive biomarker profiles in hematological malignancies: improving diagnosis, prognosis, and treatment
Ali Golestan, Mohammadrasul Zareinejad, Amin Ramezani
Biomarkers in Medicine (2025), pp. 1-16
Closed Access
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond
Durre Aden, Samreen Zaheer, Niti Sureka, et al.
Pathology - Research and Practice (2025) Vol. 269, pp. 155864-155864
Closed Access
Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients
Katarina Mirjačić Martinović, Ana Vuletić, Nevena Tišma Miletić, et al.
Translational Oncology (2023) Vol. 38, pp. 101799-101799
Open Access | Times Cited: 12
Circular RNAs: key players in tumor immune evasion
Mahla Sanati, Soudeh Ghafouri‐Fard
Molecular and Cellular Biochemistry (2025)
Closed Access
Longer survival with precision medicine in late-stage cancer patients
Christophe K. Mapendano, Anne Krogh Nøhr, Mads Sønderkær, et al.
ESMO Open (2025) Vol. 10, Iss. 1, pp. 104089-104089
Open Access
TBX3 shapes an immunosuppressive microenvironment and induces immunotherapy resistance
Zhi Liu, Chunyu Zhang, Jiatong Xiao, et al.
Theranostics (2025) Vol. 15, Iss. 5, pp. 1966-1986
Open Access
Utilizing multi-omics analysis, a new signature has been identified and validated for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma, which is based on tumor mutation burden
Dongguang Wang, Yanping Wang, Yiqun Peng, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Cancer Biology and Therapeutics: Navigating Recent Advances and Charting Future Directions

Tropical Journal of Natural Product Research (2023) Vol. 7, Iss. 12
Open Access | Times Cited: 9
SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials
Michael T Lotze, Tricia R. Cottrell, Carlo Bifulco, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e008655-e008655
Open Access | Times Cited: 3
Biological mechanisms of resistance to immune checkpoint inhibitors and overcoming this resistance: Challenges in medical oncology
Yuliia Moskalenko
Regulatory Mechanisms in Biosystems (2024) Vol. 15, Iss. 1, pp. 83-91
Open Access | Times Cited: 3
PANoptosis-related long non-coding RNA signature to predict the prognosis and immune landscapes of pancreatic adenocarcinoma
Qinying Zhao, Yingquan Ye, Quan Zhang, et al.
Biochemistry and Biophysics Reports (2023) Vol. 37, pp. 101600-101600
Open Access | Times Cited: 8
Recent Advances in Personalized Cancer Immunotherapy with Immune Checkpoint Inhibitors, T Cells and Vaccines
Elnaz Faghfuri
Personalized Medicine (2023) Vol. 21, Iss. 1, pp. 45-57
Closed Access | Times Cited: 6
Trial Design for Cancer Immunotherapy: A Methodological Toolkit
Everardo D. Saad, Elisabeth Coart, Vaiva Deltuvaite‐Thomas, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4669-4669
Open Access | Times Cited: 4
Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?
Sultana Mehbuba Hossain, Kevin Ly, Yih Jian Sung, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10120-10120
Open Access | Times Cited: 1
Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma
C. D. Fu, Haoran Gu, Lin Sun, et al.
Investigational New Drugs (2024)
Closed Access | Times Cited: 1
Mutational landscape of cancer and how latest technologies can help in simplifying the understanding
Sameer Deshmukh, Aysswarya Manoharan, Sharada Devi J N, et al.
Elsevier eBooks (2024), pp. 141-171
Closed Access | Times Cited: 1
Avelumab first‐line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial
Juliane Manitz, Aslihan Gerhold‐Ay, Pascal J. Kieslich, et al.
Cancer Medicine (2024) Vol. 13, Iss. 12
Open Access
DNA methylation variations of DNA damage response correlate survival and local immune status in melanomas
Min Wang, Xiaodong Zhang, Han‐qing Yang, et al.
Immunity Inflammation and Disease (2024) Vol. 12, Iss. 9
Open Access
AI-powered genomic mutation signature for predicting immune checkpoint inhibitor therapy outcomes in gastroesophageal cancer: a multi-cohort analysis
Bingyin Yang, Cuie Cheng, Jingfang Zhou, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access
Mitochondrial cholesterol metabolism related gene model predicts prognosis and treatment response in hepatocellular carcinoma
Xin Guo, Feng Wang, Xuejing Li, et al.
Translational Cancer Research (2024) Vol. 13, Iss. 12, pp. 6623-6644
Open Access
Special Issue “Latest Review Papers in Molecular Genetics and Genomics 2023”
Apostolos Zaravinos
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 14171-14171
Open Access
Page 1

Scroll to top